Видео ютуба по тегу Nct02005471

Impacts of the MURANO study for future CLL treatment
Impacts of the MURANO study for future CLL treatment
Results of the MURANO study for CLL
Results of the MURANO study for CLL
MURANO: five-year follow-up on venetoclax plus rituximab for CLL
MURANO: five-year follow-up on venetoclax plus rituximab for CLL
MURANO update: MRD, biological subsets & safety analysis
MURANO update: MRD, biological subsets & safety analysis
The MURANO study in CLL: 5 years on
The MURANO study in CLL: 5 years on
Venetoclax + rituximab for R/R CLL: 7-year results of the MURANO trial
Venetoclax + rituximab for R/R CLL: 7-year results of the MURANO trial
MURANO: outcomes after the end of treatment
MURANO: outcomes after the end of treatment
Update from MURANO trial: venetoclax-rituximab leads to slower clonal growth rate in CLL
Update from MURANO trial: venetoclax-rituximab leads to slower clonal growth rate in CLL
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
Venetoclax and rituximab: changing the treatment landscape in R/R CLL
Venetoclax and rituximab: changing the treatment landscape in R/R CLL
The MURANO study: key findings
The MURANO study: key findings
Venetoclax retreatment for CLL
Venetoclax retreatment for CLL
MRD: a prognostic marker in targeted therapy
MRD: a prognostic marker in targeted therapy
MURANO update: MRD negativity in CLL
MURANO update: MRD negativity in CLL
CLL: relapsed disease, discontinuation and MRD
CLL: relapsed disease, discontinuation and MRD
MURANO: venetoclax + rituximab in BIRC3-mutated R/R CLL
MURANO: venetoclax + rituximab in BIRC3-mutated R/R CLL
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
4-year update of MURANO: venR shows sustained PFS and OS benefits versus BR
4-year update of MURANO: venR shows sustained PFS and OS benefits versus BR
Updates from the MURANO trial
Updates from the MURANO trial
MURANO study: exciting times in CLL
MURANO study: exciting times in CLL